Sonidegib phosphate is under clinical development by Novartis and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sonidegib phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sonidegib phosphate overview

Sonidegib phosphate (Odomzo) is an anticancer agent. It is formulated as a hard gelatin capsules for oral route of administration. Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

It is under development for the treatment of adenocarcinoma of the gastroesophageal junction and newly diagnosed medullablastoma. It was under development for the treatment of acute lymphocytic leukemia, acute myelocytic leukemia, child-pugh A cirrhosis, pancreatic adenocarcinoma, platinum-resistant or refractory or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma, myelofibrosis, post essential thrombocythemia myelofibrosis, post polycythemia vera myelofibrosis, adenocarcinoma of esophagus or gastroesophageal junction, extensive stage small-cell lung cancer, advanced or metastatic hepatocellular carcinoma, relapsed or refractory multiple myeloma, Gorlin syndrome, sporadic superficial nodular skin basal cell carcinomas, medulloblastoma, solid tumor, hematologic malignancies and chronic myelocytic leukemia, hedgehog pathway-mutated myelodysplastic syndrome, recurrent glioblastoma multiforme, estrogen receptor negative and HER2 negative breast cancer, metastatic colorectal cancer, castration-resistant prostate cancer, steroid-refractory chronic graft versus host disease (GVHD) after allogeneic HSCT.

Novartis overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

For a complete picture of Sonidegib phosphate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.